TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11789362
Drug: Thiazide 50
Normalized name: benzthiazide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide 50 mg/day
Study: 12638027
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/d for 3 months
Study: 30563934
Drug: Afuresertib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afuresertib at 125 mg/day with intravenous paclitaxel (175 mg/m2) and carboplatin (AUC5) every 3 weeks for six cycles followed by maintenance afuresertib at 125 mg/day
Study: 27706120
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray containing liposomes, vitamins A and E (experimental arm group I)
Study: 27706120
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (sodium chloride 0.9%) (control arm group II)
Study: 26525391
Drug: Polypharmacy (use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (use of five or more drugs)
Study: 26525391
Drug: No polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No polypharmacy (less than five drugs)
Study: 26525391
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drugs
Study: 22607295
Drug: Resin salve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin salve treatment
Study: 19641054
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg administered perioperatively, 12 hours apart.
Study: 17620739
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 20 treatments at 2.0 ATA for 90 minutes
Study: 16861258
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% (2.2 ml) heavy with clonidine (75 microg) in 0.5 ml normal saline 0.9% (BC)
Study: 16861258
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% (2.2 ml) heavy with 0.5 ml normal saline 0.9% (B)
Study: 2049311
Drug: Chlorambucil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (10 mg daily for six weeks, then alternating fortnights for 12 weeks) + Interferon-alpha 2b (2 x 10(6) U/m2 three times weekly for 18 weeks)
Study: 6301364
Drug: Ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (250 mg, single intramuscular dose)
Study: 6301364
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) U, two intramuscular doses)
Study: 20808298
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of aspirin (≥ 4 times/month)
Study: 20808298
Drug: Heavy use
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy use of combined aspirin and ibuprofen (≥ 2 times/day) in males
Study: 20808298
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of ibuprofen
Study: 17950096
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg + amlodipine 5 mg
Study: 25516774
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg once daily
Study: 12241530
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1.5 g daily in three doses for 3 weeks)
Study: 10404801
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg orally once daily for 6 months (group 1)
Study: 8583588
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 2)
Study: 8552122
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg pergolide
Study: 8552122
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bromocriptine
Study: 25877711
Drug: 0.1% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bromfenac sodium eye drops, twice a day for three days before surgery and one day after surgery
Study: 23636449
Drug: Warfarin 1
Normalized name: warfarin 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 1 mg/day
Study: 23636449
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant prophylaxis
Study: 23636449
Drug: Anticoagulation (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation (both LMWH and Warfarin)
Study: 8904740
Drug: Pregnanolone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnanolone (two different formulations)
Study: 8904740
Drug: Placebo (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (not administered in this study)
Study: 6406699
Drug: 40% zinc
Normalized name: ZINC OXIDE 40 g in 100 g TOPICAL CREAM [Diaper Rash Cream 40% ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% zinc oxide ointment
Study: 6406699
Drug: Plain petrolatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain petrolatum ointment
Study: 26718808
Drug: 10 IU
Normalized name: Thyrotropin 10 IU Injection Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 IU oxytocin in Uniject (intramuscular)
Study: 25098777
Drug: Full-dose US
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose US group (0.5 ml/kg LA)
Study: 25098777
Drug: 30% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% reduced dose LA (0.35 ml/kg)
Study: 25098777
Drug: 50% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduced dose LA (0.25 ml/kg)
Study: 25098777
Drug: 70% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% reduced dose LA (0.15 ml/kg)
Study: 25098777
Drug: Neurostimulation alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurostimulation alone group (0.5 ml/kg LA)
Study: 25098777
Drug: Full-dose group
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose group
Study: 18706549
Drug: Long letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long letrozole therapy (n = 108; 219 cycles)
Study: 18706549
Drug: Short letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short letrozole therapy (n = 110; 225 cycles)
Study: 18706549
Drug: Long letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long letrozole therapy
Study: 18706549
Drug: Short letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short letrozole therapy
Study: 19001352
Drug: GIST (group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIST (group, individual, and staff therapy)
Study: 16041534
Drug: biperiden (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: biperiden (2 mg)
Study: 16041534
Drug: rivastigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rivastigmine (3 mg)
Study: 10407599
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg monthly doses)
Study: 2147752
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg once daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Study: 2147752
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg twice daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Study: 7438715
Drug: Methionine enkephalin
Normalized name: Methionine Enkephalin
DrugBank: Metenkefalin (DB12668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine enkephalin analogue DAMME infusion
Study: 30977273
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg NAC syrup, orally once daily at night for 7 consecutive days
Study: 30977273
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered similarly to NAC
Study: 22761293
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine for 7‐11 days
Study: 16318659
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% 10 mg (Group I)
Study: 16318659
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% 17.5 mg (Group II)
Study: 12393618
Drug: ATT (alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATT (alternating triple therapy)
Study: 8565029
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg twice daily
Study: 26353789
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day
Study: 26353789
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day
Study: 23879825
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) in addition to conventional medical treatment
Study: 20523087
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 on day 1 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm A)
Study: 20523087
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 on day 8 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm B)
Study: 18444053
Drug: Maudsley model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley model of family therapy for anorexia nervosa
Study: 18444053
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for bulimia nervosa
Study: 18444053
Drug: Other psychosocial
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other psychosocial interventions (family therapy, cognitive therapy, behavioral therapy)
Study: 8823423
Drug: Additional doses
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional doses of rifampicin, pyrazinamide and streptomycin every 4 weeks in the continuation phase (114 patients)
Study: 8823423
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen without additional doses (113 patients)
Study: 1395977
Drug: Corticosteroid enemas
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid enemas (CS‐‐100 mg of hydrocortisone/60 cc P.R. q.h.s.; n = 12)
Study: 1395977
Drug: Mesalamine enemas
Normalized name: mesalamine Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine enemas (5‐ASA‐‐4 g/60 cc P.R. q.h.s.; n = 19)
Study: 1395977
Drug: Short-chain fatty
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fatty acid enemas (SCFA‐‐60 cc P.R. b.i.d.; n = 14)
Study: 1395977
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment for corticosteroid enemas
Study: 1395977
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment for mesalamine enemas
Study: 1395977
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment for short-chain fatty acid enemas
Study: 2857601
Drug: Intravenous pinacidil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pinacidil, 0.2 mg/kg
Study: 2857601
Drug: Hydralazine, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine, 0.3 mg/kg
Study: 28956187
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: every-3-week ixabepilone (32 mg/m2 on day 2) + vorinostat (300 mg daily, days 1-14)
Study: 28956187
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: weekly ixabepilone (16 mg/m2 on days 2, 9, 16) + vorinostat (300 mg daily, days 1-7; 15-21)
Study: 25358221
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily before meal for 4 consecutive days monthly for 3 months
Study: 25358221
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily after meals for 3 months
Study: 20182883
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 0.5 ml dexamethasone diphosphate (10 mg)
Study: 20182883
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml placebo
Study: 19087677
Drug: TXL capsule
Normalized name: TXL
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXL capsule
Study: 11338314
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for hypertension
Study: 342623
Drug: Bivalent A/Victoria/75-A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent A/Victoria/75-A/New Jersey/76 influenza vaccine
Study: 342623
Drug: Monovalent B/Hong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent B/Hong Kong/72 influenza vaccine
Study: 342623
Drug: Bivalent A/Victoria/75-A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent A/Victoria/75-A/New Jersey/76 and Monovalent B/Hong Kong/72 influenza vaccines (given together)
Study: 27589995
Drug: L-serine (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-serine (0.5, 2.5, 7.5, or 15 g/dose, twice daily)
Study: 15290417
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg oral premedication 1 hour before induction
Study: 9360203
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg q6h)
Study: 30892844
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy
Study: 28012564
Drug: Methotrexate at
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate at a starting dose of 17.5 mg/week for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Study: 28012564
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Study: 27481744
Drug: Hypocaloric enteral
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric enteral nutrition (15 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Study: 27481744
Drug: Normocaloric enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normocaloric enteral nutrition (25 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Study: 24816958
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (20 U into internal anal sphincter)
Study: 24816958
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream (thrice daily for 6 weeks)
Study: 24816958
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (20 U)
Study: 24816958
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream
Study: 22879656
Drug: DEX 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.15 mg kg(‐1)
Study: 22879656
Drug: DEX 0.5
Normalized name: Stri-Dex 0.5 % Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.5 mg kg(‐1)
Study: 19662630
Drug: Antidepressant (ADT)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (ADT) monotherapy
Study: 17565929
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination latanoprost/timolol
Study: 9638417
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg peroral
Study: 2554500
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin fraction CY 216
Study: 28590828
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg qd
Study: 28590828
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg bid
Study: 28590828
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg qd
Study: 25425015
Drug: Felodipine sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine sustained-release tablets
Study: 20031845
Drug: Multilevel, multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel, multicomponent intervention (interactive computerized hypertension education, home BP monitoring, monthly behavioral counseling)
Study: 16678643
Drug: Acetaminophen 4
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 g/d for up to 12 months
Study: 16678643
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg/d for up to 12 months
Study: 16678643
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg/d
Study: 9412611
Drug: Lubeluzole (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole (7.5 mg over 1 hour, followed by a continuous daily infusion of 10 mg for up to 5 days)
Study: 2894247
Drug: Isoproterenol injections
Normalized name: isoproterenol Injection
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol injections
Study: 2894247
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing colforsin (forskolin), aminophylline, and yohimbine
Study: 2894247
Drug: Yohimbine cream
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine cream
Study: 2894247
Drug: Colforsin cream
Normalized name: Colforsin
DrugBank: Colforsin (DB02587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colforsin cream
Study: 2894247
Drug: Aminophylline cream
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline cream
Study: 2894247
Drug: Placebo (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (injection or cream)
Study: 22841478
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg of virus protein per 0.5 mL formulation
Study: 22841478
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg of virus protein per 0.5 mL formulation
Study: 22841478
Drug: 1.25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 μg of virus protein per 0.5 mL formulation
Study: 18688013
Drug: 15 mg/h
Normalized name: buprenorphine 0.015 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/h clazosentan
Study: 18688013
Drug: 1 mg/h
Normalized name: fentanyl 0.1 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/h clazosentan
Study: 28463833
Drug: 5 mg/h
Normalized name: fentanyl 0.05 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/h clazosentan
Study: 16187967
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release isosorbide 5' mono-nitrate (ISMN) 120 mg
Study: 16187967
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine (TD-NTG) 15 mg 24 h(‐1)
Study: 16187967
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) 10 micromol l(‐1)
Study: 16187967
Drug: Nitroglycerine (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (NTG) 100 micromol l(‐1)
Study: 16187967
Drug: ADP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADP (1 micromol l(‐1))
Study: 1993133
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase 1.5 x 10(6) IU (n = 55)
Study: 1993133
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (n = 26)
Study: 25487798
Drug: GSK1322322 (oral-i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (oral-i.v. combination)
Study: 24052491
Drug: High-dose, short-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, short-duration dietary oral supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA)
Study: 11812666
Drug: Digitalis administration
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis administration in supine position
Study: 11812666
Drug: Digitalis administration
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis administration in supine position with leg elevation
Study: 11812666
Drug: Digitalis administration
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis administration in LVD patients
Study: 10409470
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg intravenously pre-operatively
Study: 2147517
Drug: amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline (150 mg/day)
Study: 16172700
Drug: Fluoxetine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (0.25 to 0.50 mg/kg for three months)
Study: 12441944
Drug: Noncontact laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact laser therapy
Study: 16086927
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg twice a day)
Study: 10096264
Drug: Enalapril (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (standard treatment for high blood pressure)